MedTrace Logo

Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma

NCT06174545 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2023-12-18

No results posted yet for this study

Summary

This research is a clinical study with a single-blind randomized clinical trial design (randomized controlled trial) in multicenters at two Dermatology and Venereology Education centers in Indonesia.

This study aims to determine the effectiveness and safety of PSP as adjuvant therapy for melasma.

This research will be attended by 33 research subjects

Conditions

  • Melasma

Interventions

DRUG

Pigment Solution Program

adjuvant therapy for melasma that contains of combination formula consisting of morning cream - containing kojic acid, Vitamin E, Vitamin A and AquaxylTM complex; night cream - contains kojic acid, glycolic acid and AquaxylTM complex, scrub granules; and cleaning fluid containing vegetable oil and lactic acid.

Sponsors & Collaborators

  • Menarini Group

    collaborator INDUSTRY

  • Dr.dr.Irma Bernadette, SpKK (K)

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-25
Primary Completion
2023-12-18
Completion
2023-12-31

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06174545 on ClinicalTrials.gov